| Literature DB >> 33998125 |
S Platts1, J Ranawaka1, R Oliver1, S Patra-Das2, P Kotabagi3, C Neophytou4, N Shah5, M Toal2, P Bassett6, A Davison2, M Gbegbaje4, K Rao5, S Rouabhi3, S Watson2, F Odejinmi1.
Abstract
OBJECTIVE: To describe the impact of coronavirus disease 2019 (COVID-19) on the management of women with ectopic pregnancy.Entities:
Keywords: coronavirus disease 2019; fallopian tubes; methotrexate/therapeutic use; pregnancy, ectopic
Mesh:
Year: 2021 PMID: 33998125 PMCID: PMC8209857 DOI: 10.1111/1471-0528.16756
Source DB: PubMed Journal: BJOG ISSN: 1470-0328 Impact factor: 7.331
Comparison of demographic and baseline characteristics
| Variable | Category | CEPR | NCEPR |
| ||
|---|---|---|---|---|---|---|
|
|
| |||||
| Age (years) | – | 162 | 31.4 ± 5.7 | 179 | 31.6 ± 5.9 | 0.78 |
| Parity | – | 161 | 1 [0, 1] | 176 | 0 [0, 1] | 0.22 |
| Gestational age (weeks) | – | 140 | 6.7 ± 1.7 | 156 | 6.0 ± 1.6 | 0.002 |
| hCG (IU/l) | – | 153 | 1607 [647, 3792] | 174 | 1777 [877, 5221] | 0.12 |
| Ethnicity | White | 153 | 66 (43.1%) | 137 | 70 (41.9%) | 0.01 |
| Black | 20 (13.1%) | 39 (23.4%) | ||||
| Asian | 45 (29.4%) | 28 (16.8%) | ||||
| Mixed | 2 (1.3%) | 7 (4.2%) | ||||
| Other | 20 (13.1%) | 23 (13.8%) | ||||
| Risk factor for ectopic pregnancy | No | 161 | 106 (65.8%) | 179 | 96 (53.6%) | 0.02 |
| Yes | 55 (34.2%) | 83 (46.4%) | ||||
| Previous ectopic pregnancy | No | 161 | 148 (91.9%) | 179 | 145 (81.0%) | 0.004 |
| Yes | 13 (8.1%) | 34 (19.0%) | ||||
| Ectopic location | Tubal | 162 | 142 (88.8%) | 178 | 165 (92.7%) | 0.28 |
| Other | 18 (11.2%) | 13 (7.3%) | ||||
| Scar | 5 | 2 | ||||
| Interstitial/cornual | 11 | 6 | ||||
| Abdominal | 2 | 2 | ||||
| Cervical | 0 | 2 | ||||
| Ovarian | 0 | 1 | ||||
Summary statistics: mean ± standard deviation, median [interquartile range], or number (percentage).
Management of ectopic pregnancies
| Analysis | NCEPR | CEPR | Odds ratio |
| |||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| Outcome for all ectopic pregnancies | |||||||
| Complication | Unadjusted 1 | 179 | 15 (8.4%) | 162 | 12 (7.4%) | 0.87 (0.40–1.93) | 0.74 |
| Unadjusted 2 | 144 | 12 (8.3%) | 126 | 6 (4.8%) | 0.55 (0.20–1.51) | 0.25 | |
| Adjusted | 144 | – | 126 | – | 0.60 (0.20–1.78) | 0.36 | |
| Scanned within 24 hours | Unadjusted 1 | 153 | 142 (92.8%) | 156 | 140 (89.7%) | 0.68 (0.30–1.51) | 0.34 |
| Unadjusted 2 | 124 | 117 (94.4%) | 123 | 112 (91.1%) | 0.61 (0.23–1.63) | 0.32 | |
| Adjusted | 124 | – | 123 | – | 0.67 (0.23–1.95) | 0.47 | |
| Management within protocol | Unadjusted 1 | 177 | 168 (94.9%) | 160 | 154 (96.3%) | 1.38 (0.48–3.95) | 0.55 |
| Unadjusted 2 | 142 | 134 (94.4%) | 125 | 120 (96.0%) | 1.43 (0.46–4.50) | 0.54 | |
| Adjusted | 142 | – | 125 | – | 1.24 (0.35–4.32) | 0.74 | |
| Surgical management | Unadjusted 1 | 179 | 130 (72.6%) | 162 | 95 (58.6%) | 0.53 (0.34–0.84) | 0.007 |
| Unadjusted 2 | 144 | 107 (74.3%) | 126 | 68 (54.0%) | 0.41 (0.24–0.68) | 0.001 | |
| Adjusted | 144 | – | 126 | – | 0.51 (0.32–2.81) | 0.03 | |
| Non‐surgical management: medical/expectant management | |||||||
| Medical management (versus expectant) | Unadjusted 1 | 49 | 28 (57.1%) | 67 | 49 (73.1%) | 2.04 (0.93–4.46) | 0.07 |
| Unadjusted 2 | 37 | 18 (48.7%) | 58 | 42 (72.4%) | 2.77 (1.17–6.58) | 0.02 | |
| Adjusted | 37 | – | 58 | – | 3.46 (1.29–9.24) | 0.01 | |
Odds ratios reported as odds for CEPR group relative to odds for NCEPR group.
Using all patients in the analysis.
Using the same patients as in the adjusted analysis
Adjusted for: gestational age, hCG (log scale), ethnicity, risk factors for ectopic and previous ectopic pregnancy.
Only patients undergoing laparoscopy or laparotomy included in analysis. Excluding ERPC patients. Insufficient numbers of patients with a laparotomy for Analyses 2 and 3 to be performed.
Figure 1Management of ectopic pregnancies in CEPR and NCEPR.
Complications
| Complication type (30 days) |
CPER
|
NCEPR
| Clavien–Dindo grade (post‐operative) |
|---|---|---|---|
| No complication | 150 (92.6%) | 164 (91.6%) | n/a |
| Ruptured ectopic pregnancy following initial expectant/medical management | 3 (1.9%) | 4 (2.2%) | n/a |
| Conversion from laparoscopy to laparotomy | 1 (0.6%) | 3 (1.7%) | n/a |
| Significant additional intra‐operative procedure | 0 | 2 (1.1%) | n/a |
| Anaphylaxis to muscle relaxant requiring ITU admission | 1 (0.6%) | 0 | n/a |
| Methotrexate toxicity | 1 (0.6%) | 0 | n/a |
| Transfusion pre‐operatively | 0 | 1 (0.6%) | n/a |
| Transfusion pre‐methotrexate | 1 (0.6%) | 0 | n/a |
| Concurrent LRTI | 0 | 1 (0.6%) | 1 |
| Transfusion post‐operatively | 0 | 2 (1.1%) | 2 |
| Post‐operative pyrexia | 1 (0.6%) | 0 | 1 |
| Re‐presentation with post‐operative pain/bleeding | 3 (1.9%) | 1 (0.6%) | 1 |
| Re‐presentation with post‐operative infection (PID) | 1 (0.6%) | 0 | 1 |
| Re‐presentation post‐operative pain and rising hCG | 1 (0.6%) | 0 | 2 |
| Repeat laparoscopy | 0 | 1 (0.6%) | 3b |
ITU, intensive treatment unit; LRTI, lower respiratory tract infection; PID, pelvic inflammatory disease.
One patient required adhesiolysis, salpingectomy + bilateral ovarian cystectomy and one patient required salpingectomy + small bowel resection.
Same patient.
Required further management with methotrexate.
First laparoscopy for evacuation of blood and second laparoscopy for oophorectomy after ongoing rising hCG.